The event is organised by the Investor Action on AMR Initiative and was launched by the Access to Medicine Foundation, the FAIRR Initiative, the UK Department of Health & Social Care, and the Principles for Responsible Investment (PRI) at the World Economic Forum Annual Meeting in Davos in January 2020.
The virtual event will explore the financially material impacts of drug-resistant superbugs and the benefits of action to address them. The event will also introduce the first Investor Partners to the initiative, discuss upcoming activities and, importantly, why investors and financial institutions should join and how.
The keynote speech will be delivered by Professor Dame Sally Davies – UK Special Envoy on Antimicrobial Resistance & former Chief Medical Officer for England. The panel discussion will be moderated by Fiona Reynolds, CEO, PRI.
The webinar will take place on Monday, 23 November at 6-7pm CET / 5-6pm GMT / 12-1pm ET. You can register for the webinar here.
About the Investor Action on AMR Initiative
On 23rd January 2020 at the World Economic Forum Annual Meeting in Davos, the Access to Medicine Foundation, FAIRR, PRI and the UK Government launched a new initiative – Investor Action on Antimicrobial Resistance – focused on tackling the global threat of drug-resistant infections.
The main objective of the Investor Action on AMR initiative is to leverage investor influence to combat drug-resistant superbugs – an urgent public health challenge that is responsible for at least 700,000 deaths globally each year and set to rise to 10 million a year by 2050, costing the world $100 trillion USD in global economic losses.